Enterprise Value

1.464B

Cash

740.3M

Avg Qtr Burn

N/A

Short % of Float

17.45%

Insider Ownership

1.82%

Institutional Own.

-

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Linzess® (linaclotide) Details
Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder

Approved

Quarterly sales

PDUFA

Approval decision

IW-3300 Details
Endometriosis, Visceral pain, Interstitial cystitis/bladder pain syndrome

Phase 2

Data readout

CNP-104 Details
Primary biliary cholangitis, Liver disease, Autoimmune disease

Phase 2a

Data readout

Linaclotide Details
Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder, Constipation

Failed

Discontinued